COVID-19: comprehensive review on mutations and current vaccines
- PMID: 34873656
- PMCID: PMC8647783
- DOI: 10.1007/s00203-021-02606-x
COVID-19: comprehensive review on mutations and current vaccines
Abstract
Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social and economic aspects. According to WHO, viral infections continue to be a major health concern globally. Novel coronavirus, SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) causes the most recent infectious pandemic disease, COVID-19 (Coronavirus disease-19). As of now, there were 249 million infections of COVID-19 worldwide with a high mortality of more than 5 million deaths reported; and the number of new additional cases is drastically increasing. Development of therapies to treat the infected cases and prophylactic agents including vaccines that are effective towards different variants are crucial to curtail the COVID-19 pandemic. Owing to the fact that there is a high mortality and morbidity rate along with the risk of virus causing further epidemic outbursts, development of additional effective therapeutic and preventive strategies are highly warranted. Prevention, early detection and treatment will reduce the spread of COVID-19 pandemic. The present review highlights the novel mutations and therapeutic updates associated with coronaviruses along with the clinical manifestations-diagnosis, clinical management and, prophylactic and therapeutic strategies of COVID-19 infection.
Keywords: COVID-19; Clinical management; Mutations; SARS-CoV-2; Therapeutic strategies.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
-
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28. Int Rev Immunol. 2023. PMID: 35635216 Review.
-
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839. JAMA. 2020. PMID: 32648899 Review.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
-
COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.Molecules. 2020 Dec 23;26(1):39. doi: 10.3390/molecules26010039. Molecules. 2020. PMID: 33374759 Free PMC article. Review.
Cited by
-
In silico analysis of the substitution mutations and evolutionary trends of the SARS-CoV-2 structural proteins in Asia.Iran J Basic Med Sci. 2022 Nov;25(11):1299-1307. doi: 10.22038/IJBMS.2022.66649.14620. Iran J Basic Med Sci. 2022. PMID: 36474565 Free PMC article.
-
SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to downregulate MHC-I surface expression.bioRxiv [Preprint]. 2022 May 17:2022.05.17.492198. doi: 10.1101/2022.05.17.492198. bioRxiv. 2022. Update in: Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2208525120. doi: 10.1073/pnas.2208525120. PMID: 35611331 Free PMC article. Updated. Preprint.
-
Influence of SARS-CoV-2 on Adult Human Neurogenesis.Cells. 2023 Jan 6;12(2):244. doi: 10.3390/cells12020244. Cells. 2023. PMID: 36672177 Free PMC article.
-
SARS-CoV-2 in brief: from virus to prevention.Osong Public Health Res Perspect. 2022 Dec;13(6):394-406. doi: 10.24171/j.phrp.2022.0155. Epub 2022 Nov 28. Osong Public Health Res Perspect. 2022. PMID: 36617546 Free PMC article.
-
Prevention and treatment of COVID-19 infection by earthing.Biomed J. 2023 Feb;46(1):60-69. doi: 10.1016/j.bj.2022.08.002. Epub 2022 Aug 17. Biomed J. 2023. PMID: 35987499 Free PMC article.
References
-
- Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Lunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102569. - DOI - PMC - PubMed
-
- Badri KR, Aramgam S, Muppurum MK, Kona A, Kona A. Efficacy of Tinospora cordifolia in treating SARS-CoV-2: in silico studies. FASEB J. 2021;35(1):4976. doi: 10.1096/fasebj.2021.35.S1.04976. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous